Licensing Opportunities

We are harnessing the capability of our researchers to deliver innovative technologies that can be licensed to your business, organisation or government department. Learn about the technologies that are available for licensing, and keep up to date with technologies that have recently been licensed.

ADMiER

ADMiER reduces the time required to diagnose dry eye disease from an estimated 18 minutes of chair-time to just three minutes. Help us enhance clinical outcomes for patients with more accurate disease characterisation through licensing. 
Broad and ultra-potent anti-HIV-1 antibodies 

Accelerate the development of broad and ultra-potent anti-HIV-1 antibodies through licensing or direct investment.
COVID-19 vaccine platform 

A COVID-19 vaccine platform that enables rapid production of second-generation vaccines against SARS-CoV-2 variants of concern has been developed by University of Melbourne researchers.
Attenuation strategies for live rabies vaccine 

Rabies is usually fatal in people once symptoms appear. University of Melbourne researchers have identified a strategy for a safe live rabies vaccine that is able to overcome the limitations of inactivated vaccines. Partner with us to accelerate the development of therapeutic or prophylactic rabies vaccines. 
Monoclonal antibodies against COVID-19 

New SARS-CoV-2 variants have rendered ineffective most US Food and Drug Administration-approved COVID-19 antibody treatments and reduced vaccine efficacy.
New targeting strategy for lupus erythematosus

Help to accelerate the development of small molecule therapeutics against lupus erythematosus through licensing or direct investment.
Non-invasive biomarker for diabetic neuropathy

A biomarker produced in tears could be used in early diagnosis and monitoring of neuropathy in people with diabetes, in place of current invasive or difficult-to-access diagnostic methods.
Second-generation COVID-19 vaccine

First-generation COVID-19 vaccines have reduced efficacy against the emerging variants of SARS-CoV-2.

Learn more about how you can connect with us